Commercial IOL
Sponsors
SpyGlass Pharma, Inc.
Conditions
CataractGlaucomaOcular Hypertension
Phase 3
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RecruitingNCT07218783
Start: 2025-10-15End: 2031-03-31Target: 400Updated: 2025-10-20
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RecruitingNCT07218796
Start: 2025-10-28End: 2031-05-31Target: 400Updated: 2025-10-20